146 related articles for article (PubMed ID: 37144391)
21. Nonvitamin-K-antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and previous stroke or transient ischemic attack: An updated systematic review and meta-analysis of randomized controlled trials.
Ntaios G; Papavasileiou V; Diener HC; Makaritsis K; Michel P
Int J Stroke; 2017 Aug; 12(6):589-596. PubMed ID: 28730948
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients.
Lip GYH; Keshishian A; Li X; Hamilton M; Masseria C; Gupta K; Luo X; Mardekian J; Friend K; Nadkarni A; Pan X; Baser O; Deitelzweig S
Stroke; 2018 Dec; 49(12):2933-2944. PubMed ID: 30571400
[TBL] [Abstract][Full Text] [Related]
23. Outcomes of Dabigatran and Warfarin for Atrial Fibrillation in Contemporary Practice: A Retrospective Cohort Study.
Go AS; Singer DE; Toh S; Cheetham TC; Reichman ME; Graham DJ; Southworth MR; Zhang R; Izem R; Goulding MR; Houstoun M; Mott K; Sung SH; Gagne JJ
Ann Intern Med; 2017 Dec; 167(12):845-854. PubMed ID: 29132153
[TBL] [Abstract][Full Text] [Related]
24. Dabigatran Versus Warfarin for Atrial Fibrillation in Real-World Clinical Practice: A Systematic Review and Meta-Analysis.
Romanelli RJ; Nolting L; Dolginsky M; Kym E; Orrico KB
Circ Cardiovasc Qual Outcomes; 2016 Mar; 9(2):126-34. PubMed ID: 26812933
[TBL] [Abstract][Full Text] [Related]
25. Oral anticoagulants for nonvalvular atrial fibrillation in frail elderly patients: insights from the ARISTOPHANES study.
Lip GYH; Keshishian AV; Kang AL; Dhamane AD; Luo X; Li X; Balachander N; Rosenblatt L; Mardekian J; Pan X; Di Fusco M; Garcia Reeves AB; Yuce H; Deitelzweig S
J Intern Med; 2021 Jan; 289(1):42-52. PubMed ID: 32602228
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of Bleeding Events Requiring Hospitalization in Patients With Atrial Fibrillation Receiving Dabigatran, Warfarin, or Antiplatelet Therapy.
Riley TR; Gauthier-Lewis ML; Sanchez CK; Riley TT
J Pharm Pract; 2017 Apr; 30(2):214-218. PubMed ID: 26951615
[TBL] [Abstract][Full Text] [Related]
27. Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis.
Lip GY; Keshishian A; Kamble S; Pan X; Mardekian J; Horblyuk R; Hamilton M
Thromb Haemost; 2016 Oct; 116(5):975-986. PubMed ID: 27538358
[TBL] [Abstract][Full Text] [Related]
28. Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a "real-world" observational study in the United States.
Lip GY; Pan X; Kamble S; Kawabata H; Mardekian J; Masseria C; Bruno A; Phatak H
Int J Clin Pract; 2016 Sep; 70(9):752-63. PubMed ID: 27550177
[TBL] [Abstract][Full Text] [Related]
29. Major Bleeding Complications and Persistence With Oral Anticoagulation in Non-Valvular Atrial Fibrillation: Contemporary Findings in Real-Life Danish Patients.
Lamberts M; Staerk L; Olesen JB; Fosbøl EL; Hansen ML; Harboe L; Lefevre C; Evans D; Gislason GH
J Am Heart Assoc; 2017 Feb; 6(2):. PubMed ID: 28196815
[TBL] [Abstract][Full Text] [Related]
30. A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants.
Halvorsen S; Ghanima W; Fride Tvete I; Hoxmark C; Falck P; Solli O; Jonasson C
Eur Heart J Cardiovasc Pharmacother; 2017 Jan; 3(1):28-36. PubMed ID: 27680880
[TBL] [Abstract][Full Text] [Related]
31. Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulant Therapy).
Ezekowitz MD; Nagarakanti R; Noack H; Brueckmann M; Litherland C; Jacobs M; Clemens A; Reilly PA; Connolly SJ; Yusuf S; Wallentin L
Circulation; 2016 Aug; 134(8):589-98. PubMed ID: 27496855
[TBL] [Abstract][Full Text] [Related]
32. Gastrointestinal bleeding in patients with atrial fibrillation treated with Apixaban or warfarin: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.
Garcia DA; Fisher DA; Mulder H; Wruck L; De Caterina R; Halvorsen S; Granger CB; Held C; Wallentin L; Alexander JH; Lopes RD
Am Heart J; 2020 Mar; 221():1-8. PubMed ID: 31896036
[TBL] [Abstract][Full Text] [Related]
33. Oral Anticoagulation in Asian Patients With Atrial Fibrillation and a History of Intracranial Hemorrhage.
Lee SR; Choi EK; Kwon S; Jung JH; Han KD; Cha MJ; Oh S; Lip GYH
Stroke; 2020 Feb; 51(2):416-423. PubMed ID: 31813363
[TBL] [Abstract][Full Text] [Related]
34. Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation.
Hankey GJ; Stevens SR; Piccini JP; Lokhnygina Y; Mahaffey KW; Halperin JL; Patel MR; Breithardt G; Singer DE; Becker RC; Berkowitz SD; Paolini JF; Nessel CC; Hacke W; Fox KA; Califf RM;
Stroke; 2014 May; 45(5):1304-12. PubMed ID: 24743444
[TBL] [Abstract][Full Text] [Related]
35. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
Larsen TB; Skjøth F; Nielsen PB; Kjældgaard JN; Lip GY
BMJ; 2016 Jun; 353():i3189. PubMed ID: 27312796
[TBL] [Abstract][Full Text] [Related]
36. Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory Drug Therapy in Patients With Atrial Fibrillation.
Kent AP; Brueckmann M; Fraessdorf M; Connolly SJ; Yusuf S; Eikelboom JW; Oldgren J; Reilly PA; Wallentin L; Ezekowitz MD
J Am Coll Cardiol; 2018 Jul; 72(3):255-267. PubMed ID: 30012318
[TBL] [Abstract][Full Text] [Related]
37. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in atrial fibrillation: a Scandinavian population-based cohort study.
Halvorsen S; Johnsen SP; Madsen M; Linder M; Sulo G; Ghanima W; Gislason G; Hohnloser SH; Jenkins A; Al-Khalili F; Tell GS; Ehrenstein V
Eur Heart J Qual Care Clin Outcomes; 2022 Aug; 8(5):577-587. PubMed ID: 34244745
[TBL] [Abstract][Full Text] [Related]
38. Effectiveness and safety of oral anticoagulants in non-valvular atrial fibrillation patients with prior bleeding events: a retrospective analysis of administrative claims databases.
Lip GYH; Keshishian A; Kang A; Luo X; Atreja N; Zhang Y; Schuler P; Jiang J; Yuce H; Deitelzweig S
J Thromb Thrombolysis; 2022 Jul; 54(1):33-46. PubMed ID: 35579733
[TBL] [Abstract][Full Text] [Related]
39. Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation.
Norby FL; Bengtson LGS; Lutsey PL; Chen LY; MacLehose RF; Chamberlain AM; Rapson I; Alonso A
BMC Cardiovasc Disord; 2017 Sep; 17(1):238. PubMed ID: 28874129
[TBL] [Abstract][Full Text] [Related]
40. Comparison of bleeding risk scores in patients with atrial fibrillation: insights from the RE-LY trial.
Proietti M; Hijazi Z; Andersson U; Connolly SJ; Eikelboom JW; Ezekowitz MD; Lane DA; Oldgren J; Roldan V; Yusuf S; Wallentin L;
J Intern Med; 2018 Mar; 283(3):282-292. PubMed ID: 29044861
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]